Triple-Modality Peptide-Antibiotic-Phage Therapy Eradicates Multidrug-Resistant *Serratia marcescens* Biofilms

Serratia marcescens is a significant opportunistic pathogen, frequently causing severe hospital-acquired infections. A major challenge in treating these infections is the bacterium's ability to form robust biofilms and develop extensive antibiotic resistance. Current standard-of-care often struggles against these persistent, drug-resistant biofilm communities, leading to treatment failures and chronic infections. Exploring novel strategies that combine different antimicrobial mechanisms, such as peptides, traditional antibiotics, and bacteriophages, offers a promising approach to overcome these therapeutic hurdles.

Researchers evaluated a triple-modality therapy comprising antimicrobial peptides, antibiotics, and bacteriophages (BAP) against multidrug-resistant Serratia marcescens biofilms. The study design involved assessing the efficacy of each component individually and in various combinations. The primary objective was to determine the potential of this combined approach to eradicate established biofilms. The specific model (e.g., in vitro biofilm cultures) and detailed protocol parameters were not specified in the abstract.

The study evaluated the efficacy of bacteriophages, antibiotics, and antimicrobial peptides (BAP) both alone and in combination against multidrug-resistant Serratia marcescens biofilms. The research aimed to determine if this triple-modality approach could effectively eradicate these challenging bacterial structures. However, specific quantitative results, such as percentages of biofilm reduction, statistical significance, or comparisons between individual and combined treatments, were not provided in the abstract.